Seeger Weiss Llp
Professional Services |
Law Firms
55 Challenger Road, Ridgefield Park, NJ 07660
Recent News About Seeger Weiss Llp
View More
-
A federal judge has put a hold on any further proceedings in the massive, years-long nationwide legal action against Abbvie and other makers of so-called testosterone replacement therapy drugs, saying he wants to give both sides time to complete a potential settlement drug to permanently end the litigation.
-
A federal judge has knocked down a $140 million verdict against pharmaceutical maker AbbVie, ordering a new trial over a man’s claims AbbVie’s Androgel testosterone replacement therapy drug caused him to suffer a heart attack.
-
North Chicago-based drugmaker AbbVie is resisting what it is calling a jury's “confused and inconsistent” $3.2 million verdict, after the company lost a second trial in Chicago federal court – one in which it was ordered to pay $147 million less than the first trial – over a man’s claims AbbVie allegedly failed to warn its product AndroGel could bring on a heart attack.
-
About three months after a federal judge threw out a jury’s $150 million verdict and ordered a new trial in the case, a new jury in Chicago has ordered drugmaker Abbvie to pay about $3.2 million to a man who claimed Abbvie’s drug Androgel had caused him to suffer a heart attack.
-
CLEVELAND (Legal Newsline) - The judge overseeing multidistrict litigation against opioid manufacturers and distributors has named the teams of lawyers who will try to negotiate a settlement of hundreds of federal lawsuits - a complex task given parallel investigations and litigation by state attorneys general and potentially conflicting goals of private attorneys and their government counterparts.
-
After split verdicts in two prior trials over alleged harmful side effects and alleged misleading marketing of its testosterone replacement drug led to questionable verdicts worth more than $140 million each, drugmaker Abbvie has scored a clean win in the latest jury review of a plaintiff’s claims over the promotion and health impacts of Androgel.
-
CLEVELAND (Legal Newsline) - There will be a lot of familiar faces in U.S. District Judge Dan Polster’s courtroom in Cleveland on Jan. 31, when lawyers gather for a hearing on multidistrict litigation against the nation’s opioid manufacturers and distributors.
-
Saying the jury’s findings were too conflicting and inconsistent to unravel in a post-trial motion, a Chicago federal judge has instead ordered a new trial, tossing out that jury’s verdict ordering drugmaker AbbVie to pay $150 million to a man who claimed AbbVie’s promotion of its testosterone therapy drug, Androgel, led his doctor to prescribe it to him, allegedly later resulting in a heart attack.
-
North Chicago-based drug company AbbVie is urging a federal judge to trash a verdict ordering it to cough up $140 million, because its testosterone therapy drug AndroGel contributed to a man's heart attack, contending it has no liability because AndroGel was approved by the FDA.
-
Drugmaker Abbvie has suffered another big loss in court, as a Chicago federal jury has ordered the North Chicago-based pharmaceutical company to pay out $140 million to another man who claimed he had suffered a heart attack as a result of taking Abbvie’s testosterone therapy drug, Androgel.
-
A federal jury has ordered drugmaker AbbVie to pay $150 million in damages for allegedly falsely marketing the benefits of its Androgel testosterone therapy drug, even though the jury did not hold the company liable for a heart attack suffered by a man taking the drug.
